Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma

Urology

Volumn 72, Issue 4, 2008, Pages 898-902

  Marur, Shanthi ^a   Eliason, James ^a,b   Heilbrun, Lance K ^a   Dickow, Brenda ^a   Smith, Daryn W ^a   Baranowski, Karen ^a   Alhasan, Samir ^b   Vaishampayan, Ulka ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

^b Asterand   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL;

ADULT; ADVERSE DRUG REACTION; AGED; ANEMIA; ARTICLE; BONE MARROW; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HISTOLOGY; HOSPITALIZATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY FUNCTION; LIVER FUNCTION; LIVER METASTASIS; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; TAXOIDS;

EID: 52949146731     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.05.032     Document Type: Article

References (29)

1. Fyfe G., Fisher R.I., Rosenberg S.A., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688-696
2. Fisher R.I., Rosenberg S.A., Fyfe G., et al. Long term survival update for high dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6 (2000) S55-S57
3. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356 2 (2007) 115-124
4. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear cell renal carcinoma. N Engl J Med 356 2 (2007) 125-134
5. Dutcher J.P., Logan T., Gordon M., et al. Phase II trial of interleukin-2, interferon alpha and 5-fluorouracil in metastatic renal cell cancer: A cytokine working Group study. Clin Cancer Res 6 (2000) 3442-3450
6. Atzpodien J., Kirchner H., Duensing S., et al. Biochemotherapy of advanced metastatic renal cell carcinoma: Results of the combination of interleukin-2, alpha-interferon, 5-fluorouracli, vinblastine, and 13-cis-retinoic acid. World J Urol 13 3 (1995) 174-177
7. Schilsky R.L. Pharmacology and clinical status of capecitabine. Oncol (Huntington) 14 9 (2000) 1297-1306
8. Oevermann K., Buer J., Hoffman R., et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 83 5 (2000) 583-587
9. Morita T., Matsuzaki A., Tokue A., et al. Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma. Oncology 65 (2003) 125-131
10. Morita T., Matsuzaki A., Tokue A., et al. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. Int J Cancer 92 (2001) 451-456
11. Sawada N., Ishikawa T., Fukase Y., et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4 (1998) 1013-1019
12. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20 (2002) 2812-2823
13. Nadella P., Shapiro C., Otterson G.A., et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 20 (2002) 2616-2623
14. Megyeri A., Shields A., Eliason J.F., et al. Development of a stereological method to measure levels of fluoropyrimidine metabolizing enzymes in tumor sections using laser scanning cytometry. Cytometry Part A 64A (2005) 62-71
15. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
16. Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials 10 (1989) 1-10
17. Hintze J.L. Power and Sample Size (PASS) User's Guide (2004), NCSS, Kaysville, UT 277-286
18. Casella G. Refining binomial confidence intervals. Canadian J Stat 14 (1986) 113-129
19. Mehta C., and Patel N. StatXact 6: Statistical Software for Exact Nonparametric Inference, User Manual (2003), Cytel Software Corporation, Cambridge, MA 1-29
20. Lee E. Statistical Methods for Survival Data Analysis. 3rd ed. (2003), Wiley & Sons, Inc, New York, NY 76-91
21. Motzer R.J., and Vogelzang N.J. Chemotherapy for renal cell carcinoma. In: Raghavan D., Scher H.I., Leibel S.A., and Lange P. (Eds). Principles and Practice of Genitourinary Oncology (1997), Lippincott-Raven, Philadephia, PA 885-896
22. Yang J.C., Haworth L., Rosenberg S.A., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
23. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 22 (2007) 2271-2281
24. Nanus D.M., Garino A., Milowsky M.I., et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101 (2004) 1545-1551
25. Stadler W.M., Halabi S., Rini B., et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: A report of Cancer and Leukemia Group B protocol 90008. Cancer 107 (2006) 1273-1279
26. Water J.S., Moss C., Pyle L., et al. Phase II trial of capecitabine and gemcitabine in patients with metastatic renal carcinoma. Br J Cancer 91 (2004) 1763-1768
27. Friedrich C.A. Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Genet 10 (2001) 763-767
28. McDermott D.F. Update on the application of interleukin-2 in the treatment of metastatic renal carcinoma. Clin Cancer Res 13 2Suppl (2007) 716s-720s
29. Ross R.W., Eisenberg P., Vaishampayan U., et al. A phase II study of the c-met RTK inhibitor XL880 in patients with papillary renal cell carcinoma. Proc ASCO (2007) 15601